Hyphens Pharma International Ltd. · SGX:1J5
Hyphens Pharma International — Q1 2019 Earnings Presentation
8 slides from Hyphens Pharma International's earnings presentation, May 17, 2019
Slide 1: Hyphens Pharma International Limited Results Briefing 1Q2019
17/5/2019 Hyphens Pharma International Limited Results Briefing 1Q2019 HYPHENS PHARMA INTL LTD (SGX: 1J5) DISCLAIMER This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). This content in this presentation is bein
Slide 2: Key Developments 1Q2019
17/5/2019 KEY DEVELOPMENTS 1Q2019 3 OFFICIAL OPENING – Positive Feedback from invited guests – Wide media coverage -> Strong boost in Hyphens Branding 4 2
Slide 3: MOU Signing Ceremony
17/5/2019 MOU SIGNING CEREMONY – R&D collaboration activities for dermatologicals & cosmeceuticals with A*ccelerate – Target eczema, acne and pigmentary disorders – Review of new technologies with several development projects underway PLAY ON 5 SGX PUBLICATIONS 3
Slide 4: Atopic Dermatitis Range
17/5/2019 ATOPIC DERMATITIS RANGE Gentle Non-Soap Wash Maintenance Therapy Enriched with Essential Skin Lipids in a pH Balanced System * NEW! Specially-Formulated Triple Protective Action Menthol Gel to Calm & Ceramide-Dominant Mosquito Repellent For AD Against Diaper Rash Soothe Itchy Skin Therapeu
Slide 5: Launched This Year: Xcelarev and Vivomixx
17/5/2019 LAUNCHED THIS YEAR! LIGHTENS DARK SPOTS IN 3 MONTHS1 XCELAREV® A PATENTED DELIVERY SYSTEM2 WELL TOLERATED WITH LONG-TERM USE1 1 Based on data on file 2 Patent No.: UK GB 2549418 Added with vitamins 10 billion LIVE bacteria B, D and zinc in Kids formula Uses VIVOMIXX™ formula PLAY ON 5
Slide 6: Financial Highlights
17/5/2019 FINANCIAL HIGHLIGHTS 11 INCOME STATEMENT S$’000 1Q2019 1Q2018 Change % Revenue 27,004 30,628 -11.8% Gross profit 9,475 9,603 -1.3% Opex 7,923 7,503 5.6% EBITDA 2,209 2,448 -9.8% Profit before tax 1,675 2,232 -25.0% Profit, net of tax 1,429 1,794 -20.3% Earnings per share 0.48 cents 0.75 ce
Slide 7: Segment Revenue, Financial Position & Cash Flow
17/5/2019 SEGMENT REVENUE 1Q2019 1Q2018 Medical Hypermart & Digital 9,578; 9,742; 31% 13,836; 36% 17,672; 51% 3,378; 58% 3,426; 11% 13% Proprietary Specialty Pharma Brands Principals Figs in S$’000 FINANCIAL POSITION & CASH FLOW S$’000 31/3/2019 31/3/2018 Total assets 74,797 74,979 Cash & cash equiv
Slide 8: Future Growth
17/5/2019 FUTURE GROWTH • New product launches - Continue to enhance product offerings through licencing and research collaborations - Launching new specialty pharma products in regional markets • Establishing a broader geographical footprint - Cementing leadership position in Singapore and deepenin
Hyphens Pharma International — Q1 2019 Earnings Presentation on 6ix